Heron Therapeutics (HRTX) Operating Expenses (2010 - 2026)

Over the twelve months ended Jun 30, 2026, Heron Therapeutics' Operating Expenses came in at $116.8 million, up 5.7% year-over-year; for FY2025, it came in at $116.1 million, down 0.9% from FY2024.

• Operating Expenses has declined for six consecutive years, with a five-year compound annual growth rate of -18.2% (FY2020 to FY2025).
• By year, Operating Expenses came in at $117.17 million in FY2024 (-32.1%), $172.55 million in FY2023 (-24.1%), $227.46 million in FY2022 (-25.2%) and $304.17 million in FY2021 (-4.0%).
• The Q2 2026 figure ranks as the lowest quarterly Operating Expenses since Q1 2025.
• Year over year, Operating Expenses gained in three of the last eight quarters, with an average decline of 6.1%.
• The high point for year-over-year Operating Expenses in five years was Q1 2022 (growth of 19.8%); the low point was Q4 2022 (a decline of 49.1%).
• Per Business Quant data, the three quarters before Q2 2026 came in at $28.84 million (Q1 2026), $29.43 million (Q4 2025) and $30.39 million (Q3 2025).